Drug Trial Radar · NCT07889193
Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
175
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Sinovac Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a phase I, randomized, double-blind, placebo and active comparator-controlled clinical trial to evaluate the safety and immunogenicity of a trivalent split influenza virus vaccine (MDCK cell) developed by Sinovac Biotech Co., Ltd., in participants aged 6 months and above.
Conditions
- Seasonal Influenza
Interventions
Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)Biological
Investigational trivalent split influenza virus vaccine produced in MDCK cells, administered intramuscularly.
Egg-based Trivalent Split Influenza Virus Vaccine (eTIV)Biological
Licensed trivalent split influenza virus vaccine (Anflu) produced in embryonated chicken eggs, administered intramuscularly.
PlaceboOther
0.9% normal saline for intramuscular injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse reactionsTime frame: 0-28 days after each dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial Center for Disease Control and Prevention (Guangdong Academy of Preventive Medical Sciences)
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.